Optimising the treatment of upper gastrointestinal fistulae

I González-Pinto, E M González, I González-Pinto, E M González

Abstract

A three stage strategy is generally employed in the management of gastrointestinal fistulae which can form due to surgery, disease, or trauma. The condition is investigated leading to diagnosis, conservative treatment is initiated to stabilise the patient, followed by specific surgical treatment measures in complicated cases, or in the absence of spontaneous closure. Conservative management of fistulae is based on parenteral nutrition and bowel rest, as well as on control of infection, electrolytic disturbances, and local care of the fistula tract. Surgical treatment may be required although generally only in particularly serious cases. Somatostatin-14 has been used in addition to parenteral nutrition to further reduce the volume and enzymatic activity of the fluid output through the fistula tract, generally with good results. The majority of reports have shown a beneficial effect, and randomised studies have demonstrated a reduction in closure time and morbidity. However, due to a combination of the seriousness and rarity of the condition and the difficulties inherent in trial design, data from large scale, double blind, randomised, controlled studies investigating the use of pharmacotherapy in the treatment of established gastrointestinal fistulae are lacking. Nevertheless, preliminary data from initial trials suggest that somatostatin-14 and its analogue octreotide considerably improve the conservative treatment of gastrointestinal fistulae in the absence of distal obstruction. In addition, reduction of the concentration of caustic enzymes in the discharge will benefit both wound healing and nutritional losses. With reduced closure time, the period of hospitalisation will be shortened with potentially considerable economic reductions and improvements in quality of life for the patient.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1766894/bin/00691.f1.jpg
Figure 1 Conceptual algorithm for treatment with somatostatin-14. GI, gastrointestinal.
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1766894/bin/00691.f2.jpg
Figure 2 Somatostatin-14 plus nutritional support (total parenteral nutrition (TPN), enteral nutrition (EN)) may considerably reduce treatment costs.

References

    1. Acta Gastroenterol Belg. 1993 May-Aug;56(3-4):266-70
    1. Int J Pancreatol. 1993 Oct;14(2):181-8
    1. Curr Probl Surg. 1994 Jun;31(6):469-566
    1. Hepatogastroenterology. 1994 Jun;41(3):271-5
    1. Scand J Gastroenterol Suppl. 1994;207:42-4
    1. Ann Surg. 2000 Sep;232(3):419-29
    1. Arch Surg. 1971 Apr;102(4):348-52
    1. Surg Gynecol Obstet. 1974 May;138(5):710-2
    1. Science. 1975 Oct 10;190(4210):163-5
    1. Tohoku J Exp Med. 1978 Feb;124(2):99-115
    1. Ann Surg. 1979 Aug;190(2):189-202
    1. Chirurg. 1979 Jul;50(7):427-31
    1. JPEN J Parenter Enteral Nutr. 1981 Nov-Dec;5(6):496-500
    1. AJR Am J Roentgenol. 1982 Apr;138(4):615-9
    1. Br J Surg. 1982 Mar;69(3):147-50
    1. Radiology. 1982 Jul;144(2):231-7
    1. Dis Colon Rectum. 1987 Sep;30(9):705-6
    1. Prog Pediatr Surg. 1982;15:195-202
    1. World J Surg. 1983 Jul;7(4):446-50
    1. World J Surg. 1983 Jul;7(4):481-8
    1. N Engl J Med. 1983 Dec 15;309(24):1495-501
    1. JPEN J Parenter Enteral Nutr. 1984 Jan-Feb;8(1):34-6
    1. J Enterostomal Ther. 1984 Nov-Dec;11(6):211-28
    1. Acta Chir Belg. 1985 May-Jun;85(3):155-62
    1. Ann R Coll Surg Engl. 1986 Jan;68(1):5-7
    1. Scand J Gastroenterol Suppl. 1986;119:65-72
    1. Surg Gynecol Obstet. 1986 Nov;163(5):428-32
    1. Lancet. 1987 Sep 19;2(8560):672-4
    1. JPEN J Parenter Enteral Nutr. 1987 Sep-Oct;11(5):465-70
    1. Am J Surg. 1988 Jan;155(1):36-42
    1. Ann Surg. 1988 Nov;208(5):541-53
    1. J Pediatr Surg. 1988 Nov;23(11):1023-4
    1. Br J Surg. 1989 Mar;76(3):256-8
    1. J Trauma. 1989 May;29(5):584-8
    1. Gynecol Oncol. 1989 Jul;34(1):30-3
    1. Br J Surg. 1989 Jul;76(7):676-9
    1. Scand J Gastroenterol. 1989 Sep;24(7):859-62
    1. Surg Clin North Am. 1991 Feb;71(1):147-57
    1. Rev Esp Enferm Dig. 1990 Dec;78(6):345-7
    1. Br J Clin Pract. 1990 Dec;44(12):616-8
    1. Arch Surg. 1992 Jan;127(1):97-9; discussion 100
    1. Am J Surg. 1992 Feb;163(2):216-20
    1. Surg Gynecol Obstet. 1992 May;174(5):422-3
    1. Arch Surg. 1992 Jun;127(6):707-12
    1. Gut. 1992 Jun;33(6):779-82
    1. Gut. 1992 Aug;33(8):1118-22
    1. Am J Gastroenterol. 1993 Feb;88(2):307-10
    1. Acta Chir Hung. 1991;32(4):305-18
    1. Digestion. 1993;54 Suppl 1:53-8
    1. Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1213-36
    1. Br J Surg. 1995 May;82(5):638-41
    1. Surg Clin North Am. 1995 Oct;75(5):913-24
    1. West Afr J Med. 1995 Apr-Jun;14(2):97-100
    1. Nutr Hosp. 1996 Jul-Aug;11(4):226-9
    1. Surg Clin North Am. 1996 Oct;76(5):1009-18
    1. Surg Clin North Am. 1996 Oct;76(5):1019-33
    1. Surg Clin North Am. 1996 Oct;76(5):1035-80
    1. Surg Clin North Am. 1996 Oct;76(5):1081-94
    1. Surg Clin North Am. 1996 Oct;76(5):1095-109
    1. Surg Clin North Am. 1996 Oct;76(5):1111-22
    1. Surg Clin North Am. 1996 Oct;76(5):1137-46
    1. Surg Clin North Am. 1996 Oct;76(5):1159-73
    1. Surg Clin North Am. 1996 Oct;76(5):1191-8
    1. Aust N Z J Surg. 1996 Oct;66(10):668-70
    1. Rev Gastroenterol Mex. 1997 Jan-Mar;62(1):29-33
    1. Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60
    1. Am Surg. 1998 Sep;64(9):873-6
    1. Dig Dis. 1998 Jul-Aug;16(4):253-61
    1. Proc Nutr Soc. 1998 Aug;57(3):389-93
    1. Digestion. 1999;60 Suppl 2:2-8
    1. Digestion. 1999;60 Suppl 2:53-6
    1. World J Surg. 1999 Jun;23(6):560-4
    1. World J Surg. 1999 Jun;23(6):570-6
    1. Surg Clin North Am. 1987 Jun;67(3):551-71
    1. World J Surg. 2000 May;24(5):533-7; discussion 538

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren